Ingredients Categories

News

Chr. Hansen: probiotics can help minimise flu cost

2 Sep 2019

Chr. Hansen reports that a new health economics study shows that the intake of probiotics can help reduce the cost of flu-like sickness.

In the US alone, taking probiotics can reduce the number of sick days by over 54 million days per year, according to the study.

Chr. Hansen: probiotics can help minimise flu cost

Flu-like sickness can take its toll on workforce productivity, health care systems and families with young children, the company notes, and is estimated to have an annual burden on the US economy of $11.2 billion .

According to Chr. Hansen, data from numerous studies already shows a positive correlation between taking certain probiotics and reducing the number of incidents, duration and severity of flu-like sickness. This new study builds upon existing data, to assess the potential health economic impact of probiotics in the US primary care setting. The findings show the significant savings potential taking probiotics can have by reducing the number of sick days, visits to the doctor and prescriptions.

Flu-like sickness is a wide-ranging category including a fever of at least 100°F (37.8°C) and a cough or sore throat. On average over the last five years, there have been 33 million symptomatic cases in the US each year.

“Probiotics are already well established in the healthcare industry, and numerous studies have highlighted the therapeutic potential of specific probiotic strains in helping to maintain a healthy immune system and supporting the defense against harmful bacteria. In addition to the health benefits to an individual, this study demonstrates that taking probiotics also contributes to reducing costs to society and reducing the use of antibiotics. We believe that the impact of probiotics on healthcare will continue to grow in the years to come as we continue to unlock the potential of good bacteria,” said Andrew Scorey, senior vice president, Chr. Hansen Human Health.

Chr. Hansen points out that, according to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security and development today, and it is expected to exceed cancer as the main cause of death by 2050. It is estimated that more than one in three of the antibiotics prescribed to treat flu-like sickness in the US are redundant.

The new study reveals that in the US, some 2.2 million antibiotic courses could be avoided each year if the population takes probiotics.

“We already know that the overuse of antibiotics can cause bacteria to become resistant, meaning current treatments will no longer work. This study provides further evidence of how probiotics and ‘good bacteria’ can respond to some of the world’s biggest challenges,” said Scorey.

The results of the study are published in the journal Frontiers in Pharmacology and were authored and reviewed by independent industry and academic experts. Chr. Hansen sponsored the development of a new simulation model used in the study. The publication title is: Probiotics reduce healthcare cost and societal impact of flu-like respiratory tract infections in the USA: An economic modeling study.

The underlying data used in the study came from two independent reviews: York Health Economics Consortium (YHEC) and Cochrane. The clinical trials in these reviews used 22 probiotic strains, including Chr. Hansen’s Lactobacillus rhamnosus and Bifidobacterium animalis.

“This study builds on independent clinical trials and translates the clinical findings into cost and impact on primary health care. The results present a very strong case for probiotics. At Chr. Hansen, we will continue to build on these findings looking closely into how specific strains can support this health area. As a result of this study, we now have a new simulation model that will provide us with new ways to work with data in future studies,” said Adam Baker, senior manager, Human Health Development at Chr. Hansen.

Chr. Hansen owns some of the world’s best documented probiotic strains. The large number of scientific publications and clinical studies on these strains indicate that they may have beneficial effects on the immune functions.

Related news

The new geopolitics of food: How to create a resilient, self-reliant industry

The new geopolitics of food: How to create a resilient, self-reliant industry

2 Jul 2026

Today's global food system is fragile and volatile and governments must respond by building “resilient self-reliance”, says the think tank, IPES-Food.

Read more 
Pistachio supply concerns spur diversified sourcing strategies

Pistachio supply concerns spur diversified sourcing strategies

1 Jul 2026

Geopolitical and climate-change shocks have highlighted the threats to pistachio supply, prompting alternative formulations and long-term sourcing solutions.

Read more 
Arla Foods and DMK Group merge in big-dairy development

Arla Foods and DMK Group merge in big-dairy development

24 Jun 2026

International dairy company Arla Foods and German farmer-owned business DMK Group are to merge, creating one of Europe’s biggest dairy cooperatives.

Read more 
Greenpeace study finds microplastics in baby food products

Greenpeace study finds microplastics in baby food products

22 Jun 2026

A Greenpeace study found microplastics in nearly every sample taken from Nestlé’s Gerber and Danone’s Happy Baby Organics baby food plastic pouches.

Read more 
Market watch: Allergen-free no longer a 'fringe niche'

Market watch: Allergen-free no longer a 'fringe niche'

17 Jun 2026

Allergen-free food and drink products are now “structurally embedded” into the wider health and wellness category, with significant innovation happening at retail and brand level, say experts.

Read more 
IFF prepares to sell food ingredients business to CVC

IFF prepares to sell food ingredients business to CVC

16 Jun 2026

With IFF set to sell its food ingredients division to CVC Capital Partners for €3.7 billion, we look at how mergers, acquisitions, and divestments are shaping the sector.

Read more 
GLP-1 food and drink innovation: ‘Flavour still matters’

GLP-1 food and drink innovation: ‘Flavour still matters’

10 Jun 2026

Many GLP-1 users have altered flavour preferences, becoming highly nuanced and “complex”, with important implications for how brands formulate, says the Institute of Grocery Distribution.

Read more 
Ingredion’s Tate & Lyle takeover bid offers scale and science

Ingredion’s Tate & Lyle takeover bid offers scale and science

5 Jun 2026

US ingredients business Ingredion has made a £2.7bn takeover bid for its London-listed peer Tate & Lyle.

Read more 
Basic staples get a premium upgrade for at-home eating

Basic staples get a premium upgrade for at-home eating

3 Jun 2026

From Kraft Heinz’s “restaurant-style” mac and cheese to Mars’ street food-inspired noodles, brands are elevating their basic staple meals with premium versions.

Read more 
Food and drink giants call for postponements to EU packaging laws

Food and drink giants call for postponements to EU packaging laws

1 Jun 2026

Some of Europe’s biggest companies, including Coca-Cola, Kraft Heinz, McCormick, and Mondelēz, have called for new EU rules on packaging to be delayed.

Read more